The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China

20260 citationsJournal Articlegold Open Access

Authors

Ling Ma · Kunming University of Science and Technology

Jihong Duan · The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

Na Huang · Kunming University of Science and Technology

Zhiqing Zhang · Kunming University of Science and Technology

Abstract

TORI + Bev is unlikely to be cost effective compared with sorafenib for the first-line treatment of advanced HCC in China. Reducing the price of bevacizumab can increase the possibility of it being cost effective in the future.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Economic and Financial Impacts of Cancer Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Pharmacology

Volume 17, pp. 1726444-1726444

DOI: 10.3389/fphar.2026.1726444

Field-Weighted Citation Impact: 0.00